Search Within

Sergio Andres Giralt

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (55)
  2. Journal Article (41)
  3. Research Letter (3)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Bone Marrow Transplant (101)
  2. Center for Hematologic Malignancies (101)
  3. Department of Medicine (101)
  4. Department of Pathology and Laboratory Medicine (101)
  5. Hematologic Malignancies, Division of (101)
  6. Survivorship Research (85)

More Groups

People
  1. Heather Landau (55)
  2. Hani Hassoun (52)
  3. David Chung (50)
  4. Alexander Lesokhin (48)
  5. Gunjan Shah (47)
  6. Sham Mailankody (45)

More People

Years
  1. 2025 (2)
  2. 2024 (13)
  3. 2023 (15)
  4. 2022 (11)
  5. 2021 (10)
  6. 2020 (15)

More Years

Publications
  1. Blood (43)
  2. Clinical Lymphoma, Myeloma and Leukemia (9)
  3. Biology of Blood and Marrow Transplantation (6)
  4. Transplantation and Cellular Therapy (5)
  5. Journal of Clinical Investigation (4)
  6. American Journal of Hematology (3)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. Elsevier Inc. (21)
  3. Nature Publishing Group (7)
  4. American Society for Clinical Investigation (4)
  5. American Association for the Advancement of Science (3)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (101)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow up of a prospective pilot study of an α/β T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Hughes, C. F. M.; Lin, R. J.; Devlin, S. M.; Shaffer, B. C.; Jakubowski, A. A.; Talla, V.; Saldia, A.; Gyurkocza, B.; Papadopoulos, E. B.; Giralt, S. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save